Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Zogenix Shares Rose as Much as 23.8% Today

By Maxx Chatsko - Updated Jun 27, 2019 at 12:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company cleared up an issue with the FDA.

What happened

Shares of Zogenix (ZGNX) rose nearly 24% today after the company announced that it had come to an agreement with the Food and Drug Administration to resubmit a new drug application (NDA) for Fintepla, a drug candidate intended to treat seizures associated with Dravet syndrome. The development resumes the process for potentially getting the drug on the market after an embarrassing delay. 

Regulators handed Zogenix a refusal-to-file (RTF) in April. In other words, the FDA decided it wouldn't even consider Fintepla for review after finding two errors in the original NDA. The company apparently didn't include all nonclinical studies of the drug and submitted an incorrect version of a clinical data set. The issues have been cleared up after a recent meeting, and the NDA can now be submitted for review. But it won't happen until the third quarter of 2019. 

As of 11:53 a.m. EDT Thursday, the stock had settled to a 19.6% gain.

A woman checking her smartphone and pumping her fist in excitement as cash money falls around her.

Image source: Getty Images.

So what

Today's news puts Zogenix back on the path to potentially receiving marketing approval for Fintepla, but investors may want to inject some caution into their optimism. The drug is racing to compete with Epidiolex from GW Pharmaceuticals for the same indication, which makes the three-month delay potentially costly.

Now what

Will a three-month delay really matter in the long run? Well, prior to receiving the RTF letter from regulators, analysts projected that Fintepla might be able to generate peak annual sales of $600 million in Dravet syndrome by 2029. Considering that the errors in the original NDA weren't related to the drug candidate's performance, it's possible this episode is forgotten. 

That said, Zogenix is in this position because of its inexperience as a pre-commercial drug company, which is a risk investors cannot dismiss during market launch and while it is ramping up sales.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zogenix, Inc. Stock Quote
Zogenix, Inc.
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.